Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Does Not Expect Crestor Labeling Change Following Fatality

This article was originally published in The Pink Sheet Daily

Executive Summary

The company says that a fatality potentially caused by rhabdomyolysis appeared in spontaneous adverse event reporting for the cholesterol-lowering drug. AstraZeneca maintains that the evidence concerning the cause of death is more consistent with neuroleptic malignant syndrome.

You may also be interested in...



AstraZeneca’s Crestor Label Revised With Stronger Rhabdomyolysis Warnings

Labeling now emphasizes increased risk of rhabdomyolysis, especially at 40 mg dose, but FDA reaffirms that muscle toxicity is seen across the statin class and is not unique to rosuvastatin. Labeling also recommends caution in dosing in patients of Asian descent due to increased elevation in rosuvastatin exposure.

AstraZeneca’s Crestor Label Revised With Stronger Rhabdomyolysis Warnings

Labeling now emphasizes increased risk of rhabdomyolysis, especially at 40 mg dose, but FDA reaffirms that muscle toxicity is seen across the statin class and is not unique to rosuvastatin. Labeling also recommends caution in dosing in patients of Asian descent due to increased elevation in rosuvastatin exposure.

Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study

A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's clinicalstudyresults.org website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel